MEDICENNA THERAPEUTICS CORP.
Ownership & governance
Executives 5Directors 6Avg age 65Avg tenure 5.8y
FM
Fahar Merchant
Chief Executive Officer
Since 2015-02-01Profile →
+10
Executives5
RM
Rosemina Merchant→
Corporate Officer/Principal
—Since 2011-09-30
FM
Fahar Merchant→
Chief Executive Officer
—Since 2015-02-01
DH
David Hyman→
Director of Finance/CFO
—Since 2024-02-13
NI
Nageatte Ibrahim→
Chief Tech/Sci/R&D Officer
—Since 2026-04-08
CC
Christina Cameron→
Investor Relations Contact
Age 50Since 2019-01-31
Board of directors6
FM
Fahar Merchant→
Chairman
—Since 2015-02-01
AB
Albert Beraldo→
Director/Board Member
—Since 2016-11-21
JG
Jack Geltosky→
Director/Board Member
Age 80Since 2020-09-29
KL
Karim Lalji→
Director/Board Member
—Since 2024-08-14
RS
Richard Sutin→
Director/Board Member
—Since 2026-02-11
AG
Angelos Georgakis→
Director/Board Member
—Since 2026-02-11
Shareholders5
| Name | Stake | Shares |
|---|---|---|
| Fahar Merchant | 8.451 % | 5,808,802 |
| Aries Biologics, Inc. | 8.162 % | 5,610,000 |
| Rosemina Merchant | 8.142 % | 5,596,490 |
| RA Capital Management LP | 7.665 % | 5,268,788 |
| AIGH Capital Management LLC | 6.797 % | 4,672,075 |
Catalog · 2026-07-09
Registry officers11
| Name | Role | Since | Shares |
|---|---|---|---|
| David Hyman | Director of Finance/CFO | 2024-02-13 | - |
| Fahar Merchant | Chairman | 2015-02-01 | - |
| Fahar Merchant | Chief Executive Officer | 2015-02-01 | - |
| Nageatte Ibrahim | Chief Tech/Sci/R&D Officer | 2026-04-08 | - |
| Albert Beraldo | Director/Board Member | 2016-11-21 | - |
| Angelos Georgakis | Director/Board Member | 2026-02-11 | - |
| Jack Geltosky | Director/Board Member | 2020-09-29 | - |
| Karim Lalji | Director/Board Member | 2024-08-14 | - |
Registry · as of 2026-07-09
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus noneMean target 3.2Range 1.6–4Analysts 3
1.6Mean 3.24
- Buy 4
Broker actions4
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Reiterated | Buy | 2.5 | 2024-12-06 |
| Oppenheimer | Initiated | Outperform | 12 | 2020-12-18 |
| Oppenheimer | Initiated | Outperform | 12 | 2020-12-17 |
| HC Wainwright & Co. | Initiated | Buy | 8 | 2020-09-10 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.